Figure 4 : The observed (symbols) and model-predicted (lines) plasma concentration-time profiles of SHetA2 in SKOV-3-luc tumor-bearing nude mice after 10 mg/kg intravenous (○) and 60 mg/kg oral (▲) administration of SHetA2.

Woo et al.Journal of Pharmaceutical Technology and Drug Research  2017 6:2DOI : 10.7243/2050-120X-6-2